Ladenburg analyst Jeffrey Cohen raised the firm’s price target on Harrow (HROW) to $66 from $64 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q3 report.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow Health: Strong Growth Prospects and Strategic Market Expansion Drive Buy Rating
- Harrow Health’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating with Revised Price Target
- Harrow price target raised to $69 from $64 at H.C. Wainwright
- Harrow Health Reports Strong Q3 2025 Results
- Cantor Fitzgerald reiterates Overweight rating on Harrow, ups target to $94